CONFIRMATION OF KEY TREAT FINDINGS IN RED-HF, A PLACEBO CONTROLLED HEART FAILURE TRIAL

The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) demonstrated a heightened risk of stroke associated with Darbepoetin alfa (DA) use. Although stroke was not a primary endpoint, this finding raised significant patient safety concerns. The Reduction of Events by Darbepoetin Alfa